Performance of a clinical/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus.

Abstract

Background:

Patients with diabetes mellitus (DM) are at substantial risk of developing peripheral artery disease (PAD). We recently developed a clinical/proteomic panel to predict obstructive PAD. In this study, we compare the accuracy of this panel for the diagnosis of PAD in patients with and without DM.

Methods and results:

The HART PAD panel consists of one clinical variable (history of hypertension) and concentrations of six biomarkers (midkine, kidney injury molecule-1, interleukin-23, follicle-stimulating hormone, angiopoietin-1 and eotaxin-1). In a prospective cohort of 354 patients undergoing peripheral and/or coronary angiography, performance of this diagnostic panel to detect ≥50% stenosis in at least one peripheral vessel was assessed in patients with (n=94) and without DM (n=260). The model had an area under the receiver operating characteristic curve (AUC) of 0.85 for obstructive PAD. At optimal cut-off, the model had 84% sensitivity, 75% specificity, positive predictive value (PPV) of 84% and negative predictive value (NPV) of 75% for detection of PAD among patients with DM, similar as in those without DM. In those with DM, partitioning the model into five levels resulted in a PPV of 95% and NPV of 100% in the highest and lowest levels, respectively. Abnormal scores were associated with a shorter time to revascularisation during 4.3 years of follow-up.

Conclusion:

A clinical/biomarker model can predict with high accuracy the presence of PAD among patients with DM.

Trial registration number:

NCT00842868.

• Authors: Cian P McCarthy, Shreya Shrestha, Nasrien Ibrahim, Roland R J van Kimmenade, Hanna K Gaggin, Renata Mukai, Craig Magaret, Grady Barnes, Rhonda Rhyne, Joseph M Garasic, James L Januzzi
• Journal: Open heart (Open Heart) 2019 Vol. 6 Issue 1 Pg. e000955 ISSN: 2053-3624 [Print] England
• PMID: 31217993 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)